A Phase I Dose-Escalation Study Of The Selective PKC-β Inhibitor MS- 553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Trial Profile

A Phase I Dose-Escalation Study Of The Selective PKC-β Inhibitor MS- 553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2018

At a glance

  • Drugs MS 553 (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Sponsors MingSight Pharmaceuticals
  • Most Recent Events

    • 29 May 2018 Status changed from not yet recruiting to recruiting.
    • 12 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top